Cwm LLC Buys 157 Shares of Masimo Co. (NASDAQ:MASI)

Cwm LLC lifted its stake in shares of Masimo Co. (NASDAQ:MASI) by 13.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,318 shares of the medical equipment provider’s stock after acquiring an additional 157 shares during the period. Cwm LLC’s holdings in Masimo were worth $154,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Massachusetts Financial Services Co. MA bought a new position in shares of Masimo during the 3rd quarter valued at $132,699,000. Eminence Capital LP bought a new position in shares of Masimo during the third quarter valued at about $90,859,000. Hawk Ridge Capital Management LP increased its holdings in shares of Masimo by 124.4% in the third quarter. Hawk Ridge Capital Management LP now owns 567,765 shares of the medical equipment provider’s stock worth $49,782,000 after buying an additional 314,763 shares during the period. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of Masimo by 2.1% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 413,815 shares of the medical equipment provider’s stock valued at $48,503,000 after acquiring an additional 8,498 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in Masimo by 224.5% during the 3rd quarter. Sei Investments Co. now owns 183,940 shares of the medical equipment provider’s stock valued at $16,128,000 after acquiring an additional 127,249 shares during the period. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MASI. Piper Sandler lifted their price target on Masimo from $70.00 to $117.00 and gave the stock a “neutral” rating in a research note on Monday, February 26th. StockNews.com upgraded shares of Masimo from a “sell” rating to a “hold” rating in a report on Friday, March 29th. Wells Fargo & Company raised shares of Masimo from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $117.00 to $160.00 in a research report on Monday, March 25th. BTIG Research boosted their price objective on shares of Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $121.00 price objective (up from $107.00) on shares of Masimo in a research note on Tuesday, January 30th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $137.43.

Masimo Trading Up 0.6 %

NASDAQ:MASI opened at $137.00 on Monday. Masimo Co. has a 12 month low of $75.22 and a 12 month high of $188.76. The company has a current ratio of 2.18, a quick ratio of 1.22 and a debt-to-equity ratio of 0.64. The company has a 50-day moving average price of $136.10 and a 200-day moving average price of $118.80. The stock has a market cap of $7.25 billion, a price-to-earnings ratio of 90.73 and a beta of 0.99.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 EPS for the quarter, topping the consensus estimate of $0.82 by $0.43. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The business had revenue of $548.90 million during the quarter, compared to analyst estimates of $545.69 million. During the same period last year, the business posted $1.32 earnings per share. Masimo’s quarterly revenue was down 11.0% compared to the same quarter last year. Equities analysts predict that Masimo Co. will post 3.51 EPS for the current year.

Insider Activity at Masimo

In other Masimo news, Director Craig B. Reynolds sold 40,000 shares of the stock in a transaction on Friday, April 26th. The stock was sold at an average price of $136.17, for a total value of $5,446,800.00. Following the completion of the transaction, the director now owns 7,406 shares in the company, valued at $1,008,475.02. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 9.70% of the stock is currently owned by corporate insiders.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.